Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis Press release
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology Press release
Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024 Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence Press release
